In the regions of North Africa and the Middle East, GT4 has been reported to represent 65% of HCV infections 3, 4 ; this includes the country of Egypt where 90% of HCV infections are caused by GT4
and around 15% of the general population is seropositive for HCV antibodies. 1, 5, 6 Subtype distribution of GT4 also varies by country, with a high incidence of subtype 4a in Egypt, 5, 7, 8 while subtypes 4a
and 4d are common in Europe 6,7,9-11 and more heterogeneous GT4
subtypes have been reported throughout Central and Eastern subSaharan Africa. 7, [12] [13] [14] [15] In the era of direct-acting antiviral (DAA) therapies for HCV, treatment options for GT4-infected patients have expanded to interferon (IFN)-free regimens with or without ribavirin (RBV), including elbasvir/grazoprevir, 16 glecaprevir/pibrentasvir, 17, 18 ombitasvir/paritaprevir/ritonavir (OBV/PTV/r), [19] [20] [21] sofosbuvir (SOF), 22 SOF plus daclatasvir (DCV), 23 SOF plus simeprevir, 23 SOF/ledipasvir (LDV) 24 and SOF/velpatasvir. 25 Ombitasvir (OBV) is a nonstructural protein 5A (NS5A) inhibitor, and paritaprevir (PTV) is an NS3/4A inhibitor (identified by AbbVie and Enanta) codosed with ritonavir. In the phase 2b/3 PEARL-I 21 and AGATE-I 19, 20 studies, high sustained virologic response rates 12 weeks after the last dose of study drug (SVR12) were achieved in HCV GT4-infected patients without cirrhosis or with compensated cirrhosis treated with OBV/PTV/r plus RBV for 12 weeks of duration. This report utilizes a large database of NS5A gene sequences that included 17 GT4 subtypes isolated from the baseline samples of GT4-infected patients in the PEARL-I and AGATE-I studies to assess the genetic diversity of GT4 by geographic region, analyse patient demographics, examine NS5A sequence variability across GT4 subtypes and impact on treatment outcome in GT4-infected patients treated with OBV/PTV/r plus RBV, and assess OBV activity against a panel of NS5A GT4 clinical isolates.
| MATERIAL S AND ME THODS

| Clinical study design
The PEARL-I study (ClinicalTrials.gov identifier NCT01685203) was a randomized, open-label phase 2b study that evaluated the safety and efficacy of ombitasvir plus paritaprevir/r with or without RBV in noncirrhotic, treatment-naïve and pegylated-interferon (pegIFN)-RBV treatment-experienced HCV GT4-infected patients for 12 weeks of duration. 21, 26 The AGATE-I study (ClinicalTrials.gov identifier NCT02265237) was a randomized, open-label phase 3 study that evaluated the safety and efficacy of OBV/PTV/r plus RBV in treatment-naïve, IFN-RBV treatment-experienced, and SOF plus RBV ± pegIFN treatment-experienced HCV GT4-infected patients with compensated cirrhosis for 12, 16 or 24 weeks of duration. 19, 20 The PEARL-I and AGATE-I studies were conducted in accordance with the World Medical Association Declaration of Helsinki. The study protocols were approved by the relevant institutional review boards and regulatory agencies, and all patients provided written informed consent.
TA B L E 1 HCV GT4 subtype by country of enrolment in AGATE-I and PEARL-I
| Sample processing and sequence analysis
Hepatitis C virus genotype was determined by the Versant HCV Genotype Inno-LiPA Assay v2.0, and HCV subtype was identified by neighbour-joining phylogenetic analyses using a 329-nucleotide region of NS5B 27, 28 and full-length NS5A nucleotide sequences isolated from patient baseline samples, as previously described. 26 The final HCV GT4 subtype listed in Tables 1-3 was determined by   consensus between the NS5B and NS5A subtyping 
| Phylogenetic analysis
Population nucleotide sequences and consensus NGS nucleotide sequences (generated with an ambiguity setting of 0.25) for NS5A
were aligned using the MAFFT sequence alignment method. 30 To increase the number of sequences from Egypt, 7 additional GT4a
NS5A sequences from GenBank identified as originating from Egypt (GenBank Accession numbers: DQ988073, DQ988074, DQ988075, DQ988076, DQ988077, DQ988078, DQ988079) were included in the phylogenetic analyses; these sequences were excluded from the NS5A baseline polymorphism prevalence calculations. Maximum likelihood phylogenetic trees were constructed using PHYML 31, 32 with the following parameters: HKY85 nucleotide substitution model, 33 four substitution rate categories, estimation of the transition/transversion rate ratio, estimation of the proportion of invariant sites, estimation of the gamma distribution parameter and 100 bootstrapping replicates, using Geneious software (Biomatters Ltd., Auckland, New Zealand). reporter gene, as previously described. 29 Ombitasvir activity against GT4 chimeric transient replicons was assessed as previously described. 26 Briefly, in vitro transcribed replicon RNA was transfected via electroporation into a Huh-7-derived cell line, and luciferase expression was measured 4 days post-transfection. 35 The EC 50 of ombitasvir was calculated using a nonlinear regression curve fitting to the 4-parameter logistic equation in Prism5 software (GraphPad Software, Inc., La Jolla, CA, USA). The average EC 50 value for each isolate was calculated from 2 independent experiments.
| Statistical analysis
Fisher's exact test with a two-sided significance level of 0.05 was used to compare the prevalence of baseline polymorphisms in NS5A
between subject groups, impact of baseline polymorphisms in NS5A on treatment outcome, as well as the distribution of patient demographics across GT4 subtypes.
| RE SULTS
| HCV GT4 subtype prevalence by country
Among 314 GT4-infected patients with available sequences out of 319 patients enrolled in the combined cohort from the PEARL-I and AGATE-I studies, 17 GT4 subtypes were identified from patient baseline samples. HCV sequences from three patient samples did not map to any known GT4 subtype, and may represent novel or previously undetermined subtypes. Based on country of enrolment (Table 1) , the majority of patients from North America were infected with subtype 4a, and patients from Europe were predominantly infected with subtypes 4a or 4d. Patients infected with subtypes other than 4a or 4d were generally from Belgium and France, indicating that heterogeneous, less common GT4 subtypes can be detected in some European countries.
The patient-reported country of origin ( 
| Baseline demographic characteristics by GT4 subtype
The distributions of patient birth cohort and race were significantly different across GT4 subtypes 4a, 4d and non-4a/4d (P-values <.001, Table 3 ). A large proportion (71%) of the GT4d-infected patients were born after 1959, while 74% of patients with a non-4a/4d
subtype were born prior to 1960. Patients of white race comprised 90% and 98% of the 4a-and 4d-infected populations, respectively, and patients of black race comprised 68% of the non-4a/4d-infected patient population. Of the 37 non-4a/4d-infected patients of black race, 27 patients had a known country of origin and were from an African country. polymorphisms were more prevalent in the group of sequences isolated from patients who originated from Egypt (49.3%, 33/67) compared to either the cluster of sequences isolated from patients who originated from either Europe and North America (17.4%, 12/69; Pvalue = .0001), or from Greece (0%, n = 7; P-value = .015), and the difference between the groups was statistically significant. The most common polymorphisms in subtype 4a were L28M and L30R/S, detected in 17.8% and 11.0% of the GT4a sequences, respectively. The L28M polymorphism was detected at a higher prevalence (22.4%, 15/67) in the group of sequences isolated from patients who originated from Egypt, compared to 14.5% (10/69) of sequences isolated from patients who originated from Europe and North America, although the association was not statistically significant (P-value = .27).
| Phylogenetic analysis of NS5A sequences by geographic region
In contrast, the L30R/S polymorphism was only detected in the phylogenetic subpopulation of sequences isolated from patients who originated from Egypt (23.9% of the sequences, 16/67), and the association was statistically significant (P-value <.0001).
In the PEARL-I study, HCV GT4-infected patients without cirrhosis treated with OBV/PTV/r plus RBV for 12 weeks of duration achieved an SVR12 of 100% (91/91). 21 In study AGATE-I, 19, 20 In the combined analysis, excluding patients who did not achieve SVR12 for reasons other than virologic failure, SVR12 rates for HCV GT4-infected patients treated with OBV/PTV/r plus RBV were 98.9% (94/95) and 100%
(170/170) with or without an NS5A polymorphism at baseline (Pvalue = .36, analysis counts the common T/P58 polymorphism in GT4d as wild-type), respectively, indicating that there was no impact of NS5A baseline polymorphisms on treatment outcome in PEARL-I and AGATE-I.
| Activity of ombitasvir against a panel of NS5A GT4 clinical isolates
Antiviral activity of OBV was assessed against a panel of 39 NS5A
GT4 clinical isolates that included subtypes 4a, 4b, 4d, 4f, 4g, 4k, 4o and 4r (Table 4 or 4d, respectively (Table 1) . This is consistent with previous reports of high prevalence of subtypes 4a and 4d throughout Europe among GT4-infected patients. 36 The majority of GT4d-infected patients in our cohort were born after 1959, which coincides with the spread of GT4d across Europe via intravenous drug use in recent decades. 6, 7, [9] [10] [11] 37 Our analysis also revealed that 19% (50/265) of GT4 infections in Europe resulted from subtypes other than 4a or 4d, and the majority of these patients were enrolled in Belgium and
| D ISCUSS I ON
France. In addition, patients infected with non-4a/4d subtypes were generally born prior to 1960 and were of black race. Previous studies
examining the epidemiological profile of GT4 infection in France and
Belgium have reported an association between heterogeneous GT4 subtypes and patients of African origin with an unknown route of infection. 11, 38 In Africa, high prevalence of subtype 4a exists in Egypt, 5, 7, 8 while heterogeneous GT4 subtypes (4b, 4c, 4e, 4f, 4g, 4h, etc.) account for the majority of HCV infections throughout Central and Eastern sub-Saharan Africa 7, [12] [13] [14] [15] where GT4 is thought to have originated. 39 Our analysis by patient-reported country of origin (collected for study AGATE-I) revealed that of the 97 patients infected with subtype 4a, 51.5% originated from Egypt, while 42.2% originated from
Europe or North America (Table 2 ). In addition, 90% (36/40) of the F I G U R E 2 NS5A baseline polymorphism prevalence by GT4 subtype. The baseline sequences were compared to hepatitis C virus reference sequence 4a-ED43 (GenBank accession number GU814265) for all GT4a and non-4a/4d sequences. Reference 4d-QC382 (GenBank accession number FJ462437) was used for GT4d sequences
Baseline Polymorphisms
Prevalence (%) tive to the designated reference sequence. The patient sequences were compared to HCV reference sequence 4a-ED43 (GenBank accession number GU814265) for subtypes 4a, 4b, 4f, 4g, 4k, 4o and 4r. Reference 4d-QC382 (GenBank accession number FJ462437) was used for subtype 4d sequences. For patient sequences analysed by NGS, only polymorphisms detected at ≥15% prevalence within a patients' viral population are listed. Polymorphisms detected at ≥90% prevalence are separated with a "+"; polymorphisms detected at <90% are separated with a "," and listed as a mixture of amino acids. b None indicates that there were no polymorphisms relative to the designated reference sequence. c Mean EC 50 and range for GT4a total were previously published in reference.
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d The GT4a NS5A clinical isolates had an unknown country of origin, but were genetically similar to 4a sequences isolated from patients who originated from Egypt.
TA B L E 4 Activity of ombitasvir against a panel of transient replicons containing NS5A from HCV GT4 clinical samples substantial proportion of diverse GT4 subtypes among GT4-infected patients in Europe (19%) and, to a lesser extent, North America (8%)
suggests that global distribution of GT4 subtypes is shifting with immigration patterns; this was particularly apparent in Belgium and
France.
We observed that over 51% of the GT4a-infected patients in study AGATE-I originated from Egypt where subtype 4a is predominant. 5, 7, 8 Previous studies examining the molecular evolution of HCV in Egypt reported an exponential expansion of subtype 4a beginning in the 1940s due to antischistosomiasis campaigns. 5, 7, 8 Rapid amplification and spread of GT4a due to unsafe injection practices resulted in low diversity of GT4 in the Egyptian HCV-infected population. 5, 8 We examined genetic diversity in subtype 4a by geographic region and country by conducting phylogenetic analyses of NS5A sequences, which revealed clustering within subtype 4a that seg- were L28M and L30R/S, which were detected at frequencies similar to previously published studies. 36 Our analysis demonstrated that the L30R/S polymorphism was significantly associated (P-value <.0001) with the phylogenetic subpopulation of sequences isolated from patients who originated from Egypt (23.9% of the sequences, 16/67). The combined evidence suggests that the founder effect in Egypt may have resulted in a strain of HCV subtype 4a that is genetically distinct from other strains of subtype 4a that are circulating in Europe and North America.
Egypt historically had the highest prevalence of HCV worldwide, with approximately 90% of infections caused by GT4. 7 The burden of HCV infection in Egypt has declined from 2008 to 2015 due to national treatment programmes. 40 Prior to the availability of DAA therapies for HCV, standard of care in Egypt included pegIFN plus RBV.
41
In 2014, SOF became the first DAA treatment option in Egypt, and since then other DAA regimens have become available through the national HCV treatment programme, including DCV, OBV/PTV/r, simeprevir and SOF/LDV. 40 Given the higher rate of NS5A baseline polymorphisms detected in patients who originated from Egypt in our analysis, it is important to assess the impact of baseline polymorphisms on treatment outcome for regimens containing an NS5A
inhibitor.
In GT4-infected patients treated with the NS5A inhibitor DCV (20 mg) plus pegIFN/RBV, L28M in combination with L30H/S in NS5A emerged in patients experiencing virologic failure. 42 In GT4a, DCV has a 10-fold reduction in antiviral activity against the L28M or L30R NS5A polymorphisms, while L30S or the combination of L28M 44 suggesting that DCV should be combined with another DAA to overcome the reduction in antiviral activity against NS5A baseline polymorphisms in GT4.
High SVR12 rates of 96.2% or 95.4% were reported in HCV GT4-infected patients treated with either OBV/PTV/r (n = 122) or SOF/LDV (n = 130), respectively, with or without RBV in a realworld setting, but an analysis of the prevalence of NS5A baseline polymorphisms was not included in the study results. 45 Another study reported SVR12 rates of 93% (41/44) in GT4-infected patients treated with SOF/LDV, which included 25 patients with baseline polymorphisms L28M and/or L30R/S in NS5A; all 3 virologic failures had L28M/V with or without L30R in NS5A at baseline, 46 which corresponds with a 37-to 67-fold change in LDV activity against L28M/V and L30R in GT4. 47 In our combined cohort analysis, SVR12 rates of 98.9% (94/95) were observed for HCV GT4- (Table 4 ).
In conclusion, 17 GT4 subtypes were identified in the PEARL-I and AGATE-I studies among GT4-infected patients treated with OBV/PTV/r with or without RBV. Subtype prevalence by country of enrolment and country of origin suggested that global immigration patterns are changing the distribution of GT4 subtypes, which could be extrapolated to include genetically distinct viral strains within a given subtype. The distributions of birth cohort and race were also significantly different across GT4 subtypes 4a, 4d, and non-4a/4d, which correlated with the known transmission route of GT4d and the historical origin of non-4a/4d subtypes from Africa. In addition, phylogenetic and baseline polymorphism analyses of NS5A sequences suggested that a genetically distinct strain of subtype 4a may be circulating in Egypt vs Europe and North America, and the L30R/S polymorphism in NS5A was significantly associated with the Egyptian strain, although this observation needs to be confirmed with a larger sample size. Finally, NS5A baseline polymorphisms were frequently detected at resistance-associated amino acid positions for the inhibitor-class, with no impact on treatment outcome in GT4-infected patients treated with OBV/PTV/r plus RBV in the PEARL-I and AGATE-I studies. A regimen of OBV/PTV/r plus RBV for 12 weeks of duration has been approved for the treatment of HCV GT4 infection without cirrhosis or with compensated cirrhosis in the United States, 49 European Union, 50 and other global countries including Egypt.
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